Epcoritamab-bysp injection orders must be signed by a Hematology/Oncology Attending Physician
Inpatient use of epcoritamab-bysp injection is restricted to patients who meet one of the following criteria:
Initiation/new-start treatment for relapsed/refractory diffuse large B-cell lymphoma
Re-initiation of treatment in patients with relapsed/refractory diffuse large B-cell lymphoma who have experienced a treatment delay that requires re-initiation with step-up doses
All other use is restricted to outpatient encounters or clinic use only (ie, no inpatient use)
Add Formweb to your mobile device
UNC Health
System Formulary Restriction:
Epcoritamab-bysp injection orders must be signed by a Hematology/Oncology Attending Physician
Inpatient use of epcoritamab-bysp injection is restricted to patients who meet one of the following criteria:
All other use is restricted to outpatient encounters or clinic use only (ie, no inpatient use)